Ticker: ABUS

Arbutus Biopharma Corporation (NASDAQ: ABUS) has reported significant changes in its financial condition for the second quarter and first half of the year 2025. The company operates in the biopharmaceutical sector, focusing on the development of treatments for chronic hepatitis B (cHBV). Positive...